Skip to main content

Sequenom Licenses Nanopore Technology from Harvard to Develop 'Third Generation' Sequencer

NEW YORK (GenomeWeb News) - Sequenom said yesterday that it has exclusively licensed technology from Harvard University that it will use to develop a nanopore-based sequencing platform that will be faster and cheaper than currently available technologies.
The technology, which is able to detect a single strand of DNA as it passes through a nanopore, was developed by Amit Meller, an associate professor at Boston University’s Department of Biomedical Engineering. Meller invented the technology while at Harvard’s Rowland Institute.
Sequenom said it expects the technology to enable DNA sequencing, as well as whole-genome genotyping and RNA and epigenetic analysis.
Harry Stylli, CEO of Sequenom, said that the proposed system will be “complementary” to the company’s MassArray genotyping platform. "Near term we expect this nanopore technology to deliver large-scale genotyping solutions and long term we believe it has the potential to provide a commercially viable, rapid, sub-thousand dollar human genome sequencing solution," he said.
Financial terms of the license agreement include up-front fees, milestone payments, and royalties from product sales. Further details were not provided.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.